News

2021-04-26

GENE BIOTHERAPEUTICS PARTNERS WITH FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO MANUFACTURE GENERX [Ad5FGF-4] PHASE 3 ANGIOGENIC GENE THERAPY PRODUCT CANDIDATE FOR REFRACTORY ANGINA

2020-08-17

CPI partners with Perceptive Engineering and FUJIFILM Diosynth Biotechnologies to improve efficiencies in biologics manufacture

CPI has announced a partnership with Perceptive Engineering and FUJIFILM Diosynth Biotechnologies. The companies will develop a data-driven solution to improve efficiencies during downstream biologics processing, reducing the cost of manufacturing life-saving therapies.

2020-07-23

NOVAVAX AND FUJIFILM DIOSYNTH BIOTECHNOLOGIES INITIATE LARGE SCALE MANUFACTURING OF COVID-19 VACCINE CANDIDATE

Novavax, Inc. and FUJIFILM Diosynth Biotechnologies announced today an agreement to manufacture bulk drug substance for Novavax’ COVID-19 vaccine candidate.

2020-06-17

Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology

2020-06-08

Greffex Inc. Signs Manufacturing Contract with FUJIFILM Diosynth Biotechnologies to Produce Vaccines

2020-06-04

“READY TO SAVE THE WORLD” WITH MASS VACCINE MANUFACTURING

On the show, Chancellor Sharp interviewed Dr. Gerry Farrell, chief operating officer of FUJIFILM Diosynth Biotechnologies, Texas, based in College Station

2020-06-01

Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800

2020-05-07

Developing a Biomanufacturing Platform to Fill a Need

As a contract development and manufacturing organization (CDMO), FUJIFILM Diosynth Biotechnologies’ scientists and engineers need to offer flexible solutions to changing customer requirements.

2020-04-09

Fujifilm announces the start of a phase II clinical trial of its influenza antiviral drug “Avigan® Tablet” for COVID-19 patients in the U.S.

FUJIFILM Corporation announces the initiation of a U.S. phase II clinical trial to evaluate the safety and efficacy of its influenza antiviral drug “Avigan® Tablet” for patients with COVID-19, a respiratory infection caused by the novel SARS-CoV-2 coronavirus.

2020-03-06

FUJIFILM Diosynth Biotechnologies Statement on COVID-19

2018-11-29

Voyager Therapeutics Strategic Manufacturing Collaboration

2018-07-18

A Discussion with Dr. Thomas Page, VP Engineering and Asset Development at Fujifilm Diosynth Biotechnologies

2018-03-29

FUJIFILM to Acquire Irvine Scientific Sales Company

2017-10-03

Collaboration shows Improvement on Viral Production for Vaccine

2017-09-12

Science behind Saturn Process Development Laboratories

2017-07-01

Collaboration to improve downstream processing

2016-11-04

FUJIFILM Diosynth Biotechnologies awarded IChemE Award

2016-05-05

HHS pursues development of single dose nasal spray anthrax vaccineAdde

2015-11-12

Arecor, CPI and FUJIFILM Diosynth Biotechnologies collaborate

2015-10-13

FUJIFILM’s Amazing Biotechnology: Interview with Martin Meeson

2015-08-25

Bioprocess Characterization: An Interview with Graham McGreath, FUJIFILM Diosynth Biotechnologies

2015-02-01

Fujifilm’s New Biopharm Game Plan

2014-09-02